215 related articles for article (PubMed ID: 34241542)
1. Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy.
McBride A; Alrawashdh N; Bartels T; Moore L; Persky D; Abraham I
Future Oncol; 2021 Sep; 17(26):3485-3497. PubMed ID: 34241542
[TBL] [Abstract][Full Text] [Related]
2. Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab.
Cheng C; Gallagher EM; Yeh JY; Earl MA
Anticancer Drugs; 2014 Sep; 25(8):964-9. PubMed ID: 24743519
[TBL] [Abstract][Full Text] [Related]
3. Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients.
Ise M; Matsuda K; Shimura A; Masamoto Y; Kurokawa M
Int J Hematol; 2021 Jun; 113(6):823-831. PubMed ID: 33738702
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
Kataoka T; Sakurashita H; Taogoshi T; Nishigakiuchi R; Murase T; Izumitani S; Saeki Y; Matsuo H
Yakugaku Zasshi; 2019; 139(4):629-633. PubMed ID: 30930398
[TBL] [Abstract][Full Text] [Related]
5. Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy.
Kitchen K; Mosier MC
Future Oncol; 2022 Jul; 18(23):2551-2560. PubMed ID: 35708316
[TBL] [Abstract][Full Text] [Related]
6. Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer.
Alrawashdh N; Vraney J; Choi BM; Almutairi AR; Abraham I; McBride A
Future Oncol; 2022 Jun; 18(19):2381-2390. PubMed ID: 35477322
[TBL] [Abstract][Full Text] [Related]
7. Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma.
McBride A; MacDonald K; Abraham I
Leuk Res; 2021 Jul; 106():106591. PubMed ID: 33957339
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
[TBL] [Abstract][Full Text] [Related]
9. Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma.
Lokich JJ
Am J Clin Oncol; 2006 Aug; 29(4):361-3. PubMed ID: 16891862
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Yokoyama M; Kusano Y; Nishihara A; Inoue N; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
Support Care Cancer; 2020 Feb; 28(2):571-579. PubMed ID: 31093770
[TBL] [Abstract][Full Text] [Related]
11. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.
Balducci L; Mo M; Abella E; Saven A
Am J Clin Oncol; 2014 Dec; 37(6):603-10. PubMed ID: 25350463
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of same-day versus next-day administration of pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide: A retrospective multi-site analysis.
Hobbs J; Lowe J; Ferdinand A; Shook A; Beck B; Blais D; Borchardt C; Xu B
J Oncol Pharm Pract; 2023 Dec; 29(8):1853-1861. PubMed ID: 36579812
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
[TBL] [Abstract][Full Text] [Related]
15. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.
Eckstrom J; Bartels T; Abraham I; Patel H; Elquza E; Scott AJ; Malangone S; Hollings J; McBride A
Support Care Cancer; 2019 Mar; 27(3):873-878. PubMed ID: 30090991
[TBL] [Abstract][Full Text] [Related]
16. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
Langeberg WJ; Siozon CC; Page JH; Morrow PK; Chia VM
Support Care Cancer; 2014 Aug; 22(8):2167-75. PubMed ID: 24652049
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia.
Zwick C; Hartmann F; Zeynalova S; Pöschel V; Nickenig C; Reiser M; Lengfelder E; Peter N; Schlimok G; Schubert J; Schmitz N; Loeffler M; Pfreundschuh M;
Ann Oncol; 2011 Aug; 22(8):1872-7. PubMed ID: 21292644
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
19. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims.
Weycker D; Hanau A; Lonshteyn A; Bowers C; Bensink M; Garawin T; Chandler D
Curr Med Res Opin; 2018 Sep; 34(9):1705-1711. PubMed ID: 29962268
[TBL] [Abstract][Full Text] [Related]
20. An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
Zhang W; Jiang Z; Wang L; Li C; Xia J
Med Oncol; 2015 May; 32(5):147. PubMed ID: 25820754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]